›

Lung Cancer: Small Cell & Non-Small Cell

Notes

Lung Cancer: Small Cell & Non-Small Cell

Sections





Lung Cancer Types

Here we'll learn about lung cancer, with a focus on the most common forms, their causes, and histopathology. In a separate tutorial, we'll learn about lung cancer complications and staging.

Overview

Lung cancer is the result of tumors that form in the respiratory epithelium of the bronchi, bronchioles, and alveoli.

Lung cancer is a key cause of cancer death worldwide, in both men and women.

Although lung cancer is often asymptomatic in the early stages (and, thus, often goes undetected), later stages can be marked by chest pain, cough, dyspnea, and hemoptysis.

Complications of lung cancer depend on the location of tumors and the cell type; we'll address complications in more detail, elsewhere.

Often found incidentally on chest x-ray or CT.

Once a tumor is found, determination of the type of lung cancer relies on histopathology and molecular analysis.

Tobacco cigarettes contain multiple toxins and carcinogens, and smoking is the number one cause of lung cancer, accounting for 80-90% of all lung cancer cases.

Other causes include asbestos, radon, polycyclic aromatic hydrocarbons (produced when coal, wood, etc. are burned), and various metals (ex: nickel, chromium).
– Although the role of electronic cigarettes in lung cancer in humans is uncertain, studies are showing that electronic cigarettes can induce lung cancer in mice.

Most genetic mutations associated with lung cancer are non-heritable, and are associated with exposure to carcinogens.
– Genetic changes are variable, and include driver mutations, amplifications, translocations, deletions, and insertions.

Pleural mesothelioma is cancer of the lung pleura; it is most often caused by exposure to asbestos (which comprises long, thin fibers found in some building and construction materials).
– Pleural thickening and effusions are common in mesothelioma, which is notoriously difficult to treat.

Lung cancer is broadly divided into small-cell lung cancer and non-small cell lung cancer.

See additional histological slides

Small-cell Lung Cancer

Small-cell lung cancer, aka, oat cell carcinoma.
Accounts for approximately 15% of lung cancer cases.

Often centrally located, with formation of tumors in the airways submucosa and perihilar masses.
Aggressive, rapid growth and early dissemination, often to the brain, liver, and bones.

Histopathology
– Small, spindle-shaped cells with a high mitotic rate (due to rapid growth).
– Cells have scant cytoplasm and contain granular chromatin.
– Necrosis is common.
– Cancerous cells arise from neuroendocrine cells (called Kulchitsky cells) in the basal bronchial epithelium.
– Small-cell cancer may be "pure" or "combined" with large cells and/or non-small lung cancer cells.

Small-cell cancer is almost always caused by cigarette smoking.
MYC oncogene mutations and RB1 and TP53 inactivations (which facilitate uncontrolled tumor growth).

We can tie key biomarkers to the fact that these tumors arise from neuroendocrine cells:
– The following neuroendocrinal markers are often used to help identify small-cell lung cancer:
Neuron-specific enolase, Chromagranin A, Synaptophysin, and CD56.

Type of lung cancer is associated with a variety of complications, including superior vena cava syndrome, SIADH, Cushing Disease, and Lambert-Eaton syndrome.

Non-small cell lung carcinomas (NSCLC)

NSCLC Collectively account for approximately 85% of all lung cancers.

Be aware that significant WHO reclassifications occurred in 2004 and 2015 due to advances in immune-histological and molecular techniques. We will follow these updated classification schemes, but be aware of significant intertextual variation.

Adenocarcinoma

Accounts for 40% of all lung cancers.

Most commonly (though not always) found in the peripheral lung tissues, affecting airway epithelial type II alveolar cells. Distant metastases are common.

5 histological subtypes of adenocarcinoma
– More than one type may be present in a tumor
– Mucinous and non-mucinous forms exist.
– Lepidic subtype is characterized by cancer cells that follow the lining of the alveolar walls; note that there is no disruption to the respiratory tissue architecture. Adenocarcinomas with predominantly lepidic patterns have the best prognosis.
– Acinar patterns are, as their name suggests, comprised of cuboidal and/or columnar shaped cells that form acini and tubules.
– Papillary pattern comprises columnar cells surrounding a fibroblastic core.
– Micropapillary pattern is similar to papillary but smaller and lack fibroblastic cores – these small "tufts" of cells may appear to float in the alveolar spaces. Micropapillary adenocarcinoma has a relatively poor prognosis.
– Solid pattern comprises dense sheets or "nests" of cells; show that ribbons of fibrosis may weave around the nests. This pattern also has a poor prognosis.

Be aware that the subtypes "bronchoalveolar cell carcinoma" and "mixed adenocarcinoma" are no longer in use, and that "clear cell," "rhabdoid," and "signet" are now used as descriptive terms, not subtype labels.

Invasiveness of adenocarcinoma varies
– Pre-invasive forms are predominantly lepidic, and include Atypical Adenomatous Hyperplasia (AAH) and Adenocarcinoma in situ (AIS).
– Minimally invasive carcinomas comprise both lepidic and more invasive cell types that infiltrate the myofibroblastic stroma (but no invasion into the pleura or circulation). These tumors are often non-mucinous.
– Invasive adenocarcinoma is characterized by a tumor focus greater than 5 mm, and comprises a mixture of histologic patterns. Tumors are classified according to the predominant histologic pattern (for example, invasive adenocarcinoma with predominant papillary pattern). These tumors are often mucinous.

Key Points:
– Adenocarcinoma is most common lung cancer overall.
– It is the most common lung cancer in women and in non-smokers.
– Genetic mutations, including EGFR, KRAS, and ALK are associated with adenocarcinoma, and are the focus of key targeted therapies.

Squamous cell carcinoma

Accounts for approximately 30% of lung cancers.

Most often arises centrally in the bronchial tubes; however, write that peripheral tumors are associated with cavitation.

Histopathology
3 Histopathological Subtypes: basaloid, non-keratinized, and keratinized.
– Some former subtypes have been discontinued, and those subtype names are now used as descriptive terms (ex: clear cell).

– Nests of polygonal cells with eosinophilic cytoplasm and obvious nucleoli
– Under high magnification, we can see intercellular bridges.
– Keratin pearls are another common features; these are accumulations of keratin between the nests of polygonal cells.
– Necrosis may also be present.

Key Points:
– Squamous cell carcinoma is strongly associated with cigarette smoking, and with TP53 and P-450 mutations.
– A notable complication is hypercalcemia due to parathyroid hormone-related protein (PTH-rp) production; common symptoms of this include weakness, nausea, vomiting, abdominal cramps, and dehydration.

Large cell carcinoma

Accounts for approximately 10% of lung cancers.
Often peripherally located.

Histopathology: tumors comprise poorly differentiated, large cells.
Strongly associated with cigarette smoking.

It's important to know that several "subtypes" have been reclassified/reorganized; for example, this group no longer includes Large Cell Neuroendocrine Carcinoma, which is now grouped with small cell neuroendocrine tumors.

Large cell lung cancer is a diagnosis of exclusion, and diagnosis relies on surgical resection.

When relying on cytology alone, the term "non-small cell lung carcinoma, not otherwise specified" (NSCLC-NOS) is preferred.

Board Review

Lung Cancer

Getting ready for boards? Review these concise, bulleted high yield reviews for your exam.

USMLE & COMLEX-USA

Nurse Practitioner (NP)

Physician Assistant (PA)

Internal Medicine (ABIM)

References

  • ":Lung Cancer Immunotherapy | Immune Checkpoint Inhibitors." Accessed January 22, 2020. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/immunotherapy.html.
  • Anwar, Asad, Firas Jafri, Sara Ashraf, Mohammad Ali S. Jafri, and Michael Fanucchi. "Paraneoplastic Syndromes in Lung Cancer and Their Management." Annals of Translational Medicine 7, no. 15 (August 2019). https://doi.org/10.21037/atm.2019.04.86.
  • Bech, Anneke, Koen Smolders, Darryl Telting, and Hans de Boer. "Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide." Case Reports in Oncology 5, no. 1 (January 7, 2012): 1–8. https://doi.org/10.1159/000335676.
  • Brägelmann, Johannes, Stefanie Böhm, Matthew R. Guthrie, Gurkan Mollaoglu, Trudy G. Oliver, and Martin L. Sos. "Family Matters: How MYC Family Oncogenes Impact Small Cell Lung Cancer." Cell Cycle 16, no. 16 (July 24, 2017): 1489–98. https://doi.org/10.1080/15384101.2017.1339849.
  • Bubendorf, Lukas, Sylvie Lantuejoul, Adrianus J. de Langen, and Erik Thunnissen. "Nonsmall Cell Lung Carcinoma: Diagnostic Difficulties in Small Biopsies and Cytological Specimens: Number 2 in the Series 'Pathology for the Clinician' Edited by Peter Dorfmüller and Alberto Cavazza." European Respiratory Review 26, no. 144 (June 30, 2017). https://doi.org/10.1183/16000617.0007-2017.
  • "Cancer." Accessed December 17, 2019. https://www.who.int/news-room/fact-sheets/detail/cancer.
  • Castellanos, Emily H., and Leora Horn. "Immunotherapy in Lung Cancer." Cancer Treatment and Research 170 (2016): 203–23. https://doi.org/10.1007/978-3-319-40389-2_10.
  • "Cavities in the Lung in Oncology Patients: Imaging Overview and Differential Diagnoses." Accessed December 20, 2019. https://appliedradiology.com/articles/cavities-in-the-lung-in-oncology-patients-imaging-overview-and-differential-diagnoses.
  • Cesar A. Moran, M. D. "Slide Show: Non–Small-Cell Lung Cancer Pathology." Cancer Network. Accessed January 21, 2020. https://www.cancernetwork.com/slideshows/slide-show-non-small-cell-lung-cancer-pathology.
  • Chen, Huanhuan Joyce, Asaf Poran, Arun M. Unni, Sarah Xuelian Huang, Olivier Elemento, Hans-Willem Snoeck, and Harold Varmus. "Generation of Pulmonary Neuroendocrine Cells and SCLC-like Tumors from Human Embryonic Stem * * CellshESC-Derived Pulmonary Neuroendocrine Cells and Tumors." The Journal of Experimental Medicine 216, no. 3 (March 4, 2019): 674–87. https://doi.org/10.1084/jem.20181155.
  • Collisson, Eric A., Joshua D. Campbell, Angela N. Brooks, Alice H. Berger, William Lee, Juliann Chmielecki, David G. Beer, et al. "Comprehensive Molecular Profiling of Lung Adenocarcinoma." Nature 511, no. 7511 (July 2014): 543–50. https://doi.org/10.1038/nature13385.
  • Derman, Benjamin A., Kathryn F. Mileham, Philip D. Bonomi, Marta Batus, and Mary J. Fidler. "Treatment of Advanced Squamous Cell Carcinoma of the Lung: A Review." Translational Lung Cancer Research 4, no. 5 (October 2015): 524–32. https://doi.org/10.3978/j.issn.2218-6751.2015.06.07.
  • Dorantes-Heredia, Rita, José Manuel Ruiz-Morales, and Fernando Cano-García. "Histopathological Transformation to Small-Cell Lung Carcinoma in Non-Small Cell Lung Carcinoma Tumors." Translational Lung Cancer Research 5, no. 4 (August 2016): 401–12. https://doi.org/10.21037/tlcr.2016.07.10.
  • Fisseler-Eckhoff, Annette, and Melanie Demes. "Neuroendocrine Tumors of the Lung." Cancers 4, no. 3 (July 31, 2012): 777–98. https://doi.org/10.3390/cancers4030777.
  • Furrukh, Muhammad. "Tobacco Smoking and Lung Cancer." Sultan Qaboos University Medical Journal 13, no. 3 (August 2013): 345–58.
  • Gardiner, Natasha, Sanjay Jogai, and Adam Wallis. "The Revised Lung Adenocarcinoma Classification—an Imaging Guide." Journal of Thoracic Disease 6, no. Suppl 5 (October 2014): S537–46. https://doi.org/10.3978/j.issn.2072-1439.2014.04.05.
  • Ghorbani, Hosein, Mohsen Vakili Sadeghi, Tahereh Hejazian, and Majid Sharbatdaran. "Superior Vena Cava Syndrome as a Paraneoplastic Manifestation of Soft Tissue Sarcoma." Hematology, Transfusion and Cell Therapy 40, no. 1 (2018): 75–78. https://doi.org/10.1016/j.htct.2017.09.001.
  • Goldner, Whitney. "Cancer-Related Hypercalcemia." Journal of Oncology Practice 12, no. 5 (May 1, 2016): 426–32. https://doi.org/10.1200/JOP.2016.011155.
  • Großerueschkamp, Frederik, Angela Kallenbach-Thieltges, Thomas Behrens, Thomas Brüning, Matthias Altmayer, Georgios Stamatis, Dirk Theegarten, and Klaus Gerwert. "Marker-Free Automated Histopathological Annotation of Lung Tumour Subtypes by FTIR Imaging." Analyst 140, no. 7 (2015): 2114–20. https://doi.org/10.1039/C4AN01978D.
  • Hecht, Stephen S. "Lung Carcinogenesis by Tobacco Smoke." International Journal of Cancer. Journal International Du Cancer 131, no. 12 (December 15, 2012): 2724–32. https://doi.org/10.1002/ijc.27816.
  • Herbst, Roy S., Daniel Morgensztern, and Chris Boshoff. "The Biology and Management of Non-Small Cell Lung Cancer." Nature 553, no. 7689 (January 2018): 446–54. https://doi.org/10.1038/nature25183.
  • Hirsch, Fred R, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, and Luis Paz-Ares. "Lung Cancer: Current Therapies and New Targeted Treatments." The Lancet 389, no. 10066 (January 2017): 299–311. https://doi.org/10.1016/S0140-6736(16)30958-8.
  • "Histology of Lung Cancer." Accessed December 17, 2019. http://oncolex.org/Lung-cancer/Background/Histology.
    Inamura, Kentaro. "Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification." Frontiers in Oncology 7 (August 28, 2017). https://doi.org/10.3389/fonc.2017.00193.
  • Iwata, Hisashi. "Adenocarcinoma Containing Lepidic Growth." Journal of Thoracic Disease 8, no. 9 (September 2016): E1050–52. https://doi.org/10.21037/jtd.2016.08.78.
  • Jeong, Chaiho, Jinhee Lee, Seongyul Ryu, Hwa Young Lee, Ah Young Shin, Ju Sang Kim, Joong Hyun Ahn, and Hye Seon Kang. "A Case of Ectopic Adrenocorticotropic Hormone Syndrome in Small Cell Lung Cancer." Tuberculosis and Respiratory Diseases 78, no. 4 (October 2015): 436–39. https://doi.org/10.4046/trd.2015.78.4.436.
  • Kadota, Kyuichi, Jun-ichi Nitadori, Kaitlin M. Woo, Camelia S. Sima, David J. Finley, Valerie W. Rusch, Prasad S. Adusumilli, and William D. Travis. "Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic Factors for Worse Outcomes." Journal of Thoracic Oncology 9, no. 8 (August 1, 2014): 1126–39. https://doi.org/10.1097/JTO.0000000000000253.
  • Kanaji, Nobuhiro, Naoki Watanabe, Nobuyuki Kita, Shuji Bandoh, Akira Tadokoro, Tomoya Ishii, Hiroaki Dobashi, and Takuya Matsunaga. "Paraneoplastic Syndromes Associated with Lung Cancer." World Journal of Clinical Oncology 5, no. 3 (August 10, 2014): 197–223. https://doi.org/10.5306/wjco.v5.i3.197.
  • Kay, Fernando U, Asha Kandathil, Kiran Batra, Sachin S Saboo, Suhny Abbara, and Prabhakar Rajiah. "Revisions to the Tumor, Node, Metastasis Staging of Lung Cancer (8th Edition): Rationale, Radiologic Findings and Clinical Implications." World Journal of Radiology 9, no. 6 (June 28, 2017): 269–79. https://doi.org/10.4329/wjr.v9.i6.269.
  • Lázaro, Sara, Miriam Pérez-Crespo, Corina Lorz, Alejandra Bernardini, Marta Oteo, Ana Belén Enguita, Eduardo Romero, et al. "Differential Development of Large-Cell Neuroendocrine or Small-Cell Lung Carcinoma upon Inactivation of 4 Tumor Suppressor Genes." Proceedings of the National Academy of Sciences 116, no. 44 (October 29, 2019): 22300–306. https://doi.org/10.1073/pnas.1821745116.
  • Li, Shuyu D., Meng Ma, Hui Li, Aneta Waluszko, Tatyana Sidorenko, Eric E. Schadt, David Y. Zhang, Rong Chen, and Fei Ye. "Cancer Gene Profiling in Non-Small Cell Lung Cancers Reveals Activating Mutations in JAK2 and JAK3 with Therapeutic Implications." Genome Medicine 9, no. 1 (October 30, 2017): 89. https://doi.org/10.1186/s13073-017-0478-1.
  • Lim, Wanyin, Carole A. Ridge, Andrew G. Nicholson, and Saeed Mirsadraee. "The 8th Lung Cancer TNM Classification and Clinical Staging System: Review of the Changes and Clinical Implications." Quantitative Imaging in Medicine and Surgery 8, no. 7 (August 2018): 709–18. https://doi.org/10.21037/qims.2018.08.02.
  • "Lung Cancer 101 | Lungcancer.Org." Accessed January 21, 2020. https://www.lungcancer.org/find_information/publications/163-lung_cancer_101/269-non_small_cell_lung_cancer_treatment.
  • Merck Manuals Professional Edition. "Lung Carcinoma - Pulmonary Disorders." Accessed December 17, 2019. https://www.merckmanuals.com/professional/pulmonary-disorders/tumors-of-the-lungs/lung-carcinoma.
  • Moon, Youngkyu, Kyo Young Lee, Sook Whan Sung, and Jae Kil Park. "Differing Histopathology and Prognosis in Pulmonary Adenocarcinoma at Central and Peripheral Locations." Journal of Thoracic Disease 8, no. 1 (January 2016): 169–77. https://doi.org/10.3978/j.issn.2072-1439.2016.01.15.
  • DoveMed. "Non-Keratinizing Squamous Cell Carcinoma of Lung." Accessed January 20, 2020. http://www.dovemed.com/diseases-conditions/non-keratinizing-squamous-cell-carcinoma-lung/.
  • National Cancer Institute. "Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version." PdqCancerInfoSummary, October 18, 2019. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq.
  • Novello, S., F. Barlesi, R. Califano, T. Cufer, S. Ekman, M. Giaj Levra, K. Kerr, et al. "Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up." Annals of Oncology 27, no. suppl_5 (September 1, 2016): v1–27. https://doi.org/10.1093/annonc/mdw326.
  • Ouadah, Youcef, Enrique R. Rojas, Daniel P. Riordan, Sarah Capostagno, Christin S. Kuo, and Mark A. Krasnow. "Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, P53, and Notch." Cell 179, no. 2 (October 3, 2019): 403-416.e23. https://doi.org/10.1016/j.cell.2019.09.010.
  • Pelosi, Giuseppe, Angelica Sonzogni, Sergio Harari, Adriana Albini, Enrica Bresaola, Caterina Marchiò, Federica Massa, et al. "Classification of Pulmonary Neuroendocrine Tumors: New Insights." Translational Lung Cancer Research 6, no. 5 (October 2017): 513–29. https://doi.org/10.21037/tlcr.2017.09.04.
  • Popper, Helmut H. "Cons: The Confusing Mucinous Adenocarcinoma Classification." Translational Lung Cancer Research 6, no. 2 (April 2017): 234–40. https://doi.org/10.21037/tlcr.2017.04.09.
  • "Pulmonary Pathology for Medical Education - WebPath." Accessed January 20, 2020. https://webpath.med.utah.edu/LUNGHTML/LUNGIDX.html#8.
  • QIAN, XINYU, and JING QIN. "Hypertrophic Pulmonary Osteoarthropathy with Primary Lung Cancer." Oncology Letters 7, no. 6 (June 2014): 2079–82. https://doi.org/10.3892/ol.2014.2022.
    Reference, Genetics Home. "Lung Cancer." Genetics Home Reference. Accessed December 17, 2019. https://ghr.nlm.nih.gov/condition/lung-cancer.
  • Rekhtman, Natasha. "Neuroendocrine Tumors of the Lung: An Update." Arch Pathol Lab Med 134 (2010): 11.
    Rohr, A. von, T. Cerny, R. A. Joss, and K. W. Brunner. "[Syndrome of inappropriate ADH secretion (SIADH) in small-cell bronchus carcinoma]." Schweizerische Medizinische Wochenschrift 121, no. 36 (September 7, 1991): 1271–82.
  • Rolfo, Christian, Francesco Passiglia, Marcin Ostrowski, Lúcia Farracho, Tereza Ondøichová, Ana Dolcan, Marta Castiglia, Roy Remmen, Konstantinos Papadimitriou, and Patrick Pauwels. "Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians." The Journal of the American Board of Family Medicine 28, no. 1 (January 1, 2015): 124–33. https://doi.org/10.3122/jabfm.2015.01.140072.
  • Solis, Luisa M., Carmen Behrens, M. Gabriela Raso, Heather Y. Lin, Humam Kadara, Ping Yuan, Hector Galindo, et al. "Histologic Patterns and Molecular Characteristics of Lung Adenocarcinoma Associated With Clinical Outcome." Cancer 118, no. 11 (June 1, 2012): 2889–99. https://doi.org/10.1002/cncr.26584.
  • Suarez, Eric, and Barbara E. C. Knollmann-Ritschel. "Squamous Cell Carcinoma of the Lung." Academic Pathology 4 (July 24, 2017). https://doi.org/10.1177/2374289517705950.
  • Swanton, Charles, and Ramaswamy Govindan. "Clinical Implications of Genomic Discoveries in Lung Cancer." New England Journal of Medicine 374, no. 19 (May 12, 2016): 1864–73. https://doi.org/10.1056/NEJMra1504688.
  • TANE, SHINYA, WATARU NISHIO, HIROYUKI OGAWA, DAISUKE HOKKA, KENTA TANE, YUGO TANAKA, SHUNSUKE TAUCHI, et al. "Clinical Significance of the 'Not Otherwise Specified' Subtype in Candidates for Resectable Non-Small Cell Lung Cancer." Oncology Letters 8, no. 3 (September 2014): 1017–24. https://doi.org/10.3892/ol.2014.2302.
  • Tang, Moon-shong, Xue-Ru Wu, Hyun-Wook Lee, Yong Xia, Fang-Ming Deng, Andre L. Moreira, Lung-Chi Chen, William C. Huang, and Herbert Lepor. "Electronic-Cigarette Smoke Induces Lung Adenocarcinoma and Bladder Urothelial Hyperplasia in Mice." Proceedings of the National Academy of Sciences 116, no. 43 (October 22, 2019): 21727–31. https://doi.org/10.1073/pnas.1911321116.
  • Travis, William D., Elisabeth Brambilla, Allen P. Burke, Alexander Marx, and Andrew G. Nicholson. "Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart." Journal of Thoracic Oncology 10, no. 9 (September 1, 2015): 1240–42. https://doi.org/10.1097/JTO.0000000000000663.
  • Travis, William D., Elisabeth Brambilla, Andrew G. Nicholson, Yasushi Yatabe, John H.M. Austin, Mary Beth Beasley, Lucian. R. Chirieac, et al. "The 2015 World Health Organization Classification of Lung Tumors." Journal of Thoracic Oncology 10, no. 9 (September 2015): 1243–60. https://doi.org/10.1097/JTO.0000000000000630.
  • "Treatment of Mesothelioma Based on the Extent of the Cancer." Accessed January 21, 2020. https://www.cancer.org/cancer/malignant-mesothelioma/treating/by-extent.html.
    Uruga, Hironori, Takeshi Fujii, and Kazuma Kishi. "What Is Spread through Air Space?" Journal of Thoracic Disease 9, no. 10 (October 2017): E943–44. https://doi.org/10.21037/jtd.2017.08.159.
  • Villalobos, Pamela, and Ignacio I. Wistuba. "Lung Cancer Biomarkers." Hematology/Oncology Clinics of North America 31, no. 1 (February 2017): 13–29. https://doi.org/10.1016/j.hoc.2016.08.006.
  • Warth, Arne. "Spread through Air Spaces (STAS): A Comprehensive Update." Translational Lung Cancer Research 6, no. 5 (October 2017): 501–7. https://doi.org/10.21037/tlcr.2017.06.08.
  • "What Are Lung Carcinoid Tumors?" Accessed December 17, 2019. https://www.cancer.org/cancer/lung-carcinoid-tumor/about/what-is-lung-carcinoid-tumor.html.
  • "What Is Lung Cancer? | Types of Lung Cancer." Accessed December 17, 2019. https://www.cancer.org/cancer/lung-cancer/about/what-is.html.
  • "Who Should Be Screened for Lung Cancer? | CDC," November 18, 2019. https://www.cdc.gov/cancer/lung/basic_info/screening.htm.
  • Zamay, Tatiana N., Galina S. Zamay, Olga S. Kolovskaya, Ruslan A. Zukov, Marina M. Petrova, Ana Gargaun, Maxim V. Berezovski, and Anna S. Kichkailo. "Current and Prospective Protein Biomarkers of Lung Cancer." Cancers 9, no. 11 (November 13, 2017). https://doi.org/10.3390/cancers9110155.
  • Zappa, Cecilia, and Shaker A. Mousa. "Non-Small Cell Lung Cancer: Current Treatment and Future Advances." Translational Lung Cancer Research 5, no. 3 (June 2016): 288–300. https://doi.org/10.21037/tlcr.2016.06.07.
  • Zhang, Bin, Yueying Zhang, and Dongmei Yu. "Lung Cancer Gene Therapy: Transferrin and Hyaluronic Acid Dual Ligand-Decorated Novel Lipid Carriers for Targeted Gene Delivery." Oncology Reports 37, no. 2 (February 1, 2017): 937–44. https://doi.org/10.3892/or.2016.5298.